Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2026)

Crinetics Pharmaceuticals' Receivables - Other history runs 10 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 23.97% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (up 23.97% YoY), while the FY2025 annual figure was $7.8 million, down 6.64% from the prior year.
• Receivables - Other was $9.0 million for Q1 2026 at Crinetics Pharmaceuticals, up from $7.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $9.0 million in Q1 2026 to a low of $92000.0 in Q3 2022.
• Historically, Receivables - Other has averaged $3.8 million across 5 years, with a median of $3.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other slumped 96.49% in 2024, then soared 6791.3% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.4 million in 2022, then soared by 125.5% to $3.1 million in 2023, then jumped by 172.37% to $8.3 million in 2024, then retreated by 6.64% to $7.8 million in 2025, then advanced by 15.46% to $9.0 million in 2026.
• The last three Receivables - Other figures came in at $9.0 million (Q1 2026), $7.8 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.